

Supplementary Table 1. Trial Design

	Screening period		Placebo period		Follow-up period					Single-dose period		Follow-up period					Repeated-dose period								Follow-up period			
Time	D-2	D-1	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	D12	D13	D14	D15	D16	D17	D18	D19	D20	D21	D22	D23	D24	D25	D26
Vital signs	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Physical examination	X								X	X														X				
Drug administration			qd							qd							tid	tid	tid	tid	tid	tid	tid	qd				
ECG	X	X	X	X						X	X	X	X				X						X	X	X	X	X	
Hematology	X			X						X	X						X							X	X			
Blood chemistry	X			X						X	X						X							X	X			
HBs-Ag	X																								X			
HCV-Ab	X																								X			
HIV	X																								X			
Blood sugar	X		X							X														X				
Insulin	X		X							X														X				
C-peptide	X		X							X														X				
Glucagon			X							X														X				
GLP-1			X							X														X				
Urinanalysis	X			X						X	X						X							X	X			
Urine microscopic evaluation	X			X						X	X						X							X	X			
Urine pregnancy test	X																								X			
Glycated Albumin	X																X								X			
GABA			X							X														X				

Drug administration, qd: 2g/day; tid: 2g×3/day

Time: D, day